TEWKSBURY, Mass.--(BUSINESS WIRE)--Cambridge Heart, Inc. (OTCBB: CAMH), today announced a strategy aimed at increasing the sales and use of its proprietary Microvolt T-Wave Alternans (MTWA) technology, which can predict a patient’s risk of sudden cardiac arrest (SCA). The strategy calls for the Company to partner with manufacturers of cardiac stress testing equipment to develop an OEM MTWA Module that will be integrated into their systems, and marketed to a much larger number of cardiologists and internal medicine practitioners.
